{"filings":[{"id":470358,"accession_number":"0001625297-26-000024","cik":1625297,"company_name":"Indivior Pharmaceuticals, Inc.","ticker":"INDV","form_type":"8-K","filed_at":"2026-05-15T20:01:51+00:00","items":["5.02","5.07"],"status":"ready","headline":"Indivior eliminates Chief Scientific Officer role; Heidbreder to depart Dec 31, 2026","event_type":"leadership","confidence":"high","bullets":["CSO position eliminated effective June 1, 2026; Dr. Christian Heidbreder transitions to advisory role through year-end.","Heidbreder's employment terminates Dec 31, 2026 as a termination without cause per existing agreement.","At May 13 annual meeting, shareholders elected all eight director nominees with overwhelming support.","Say-on-pay approved; frequency set to annual until 2032 unless board changes.","Ratification of PwC as independent auditor for fiscal 2026 passed with 99.1M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94167,"accession_number":"0001625297-26-000021","cik":1625297,"company_name":"Indivior Pharmaceuticals, Inc.","ticker":"INDV","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Indivior launches $175M accelerated share repurchase with Barclays","event_type":"other_material","confidence":"high","bullets":["Initial prepayment of $175M; received 3,717,473 shares from Barclays.","Final share count based on VWAP during term; settlement by June 22, 2026.","Part of existing $400M buyback program; $100M remains for future repurchases.","Company reaffirms prior financial guidance; ASR reflects confidence in strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94166,"accession_number":"0001193125-26-193925","cik":1625297,"company_name":"Indivior Pharmaceuticals, Inc.","ticker":"INDV","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Indivior Q1 net revenue $317M (+19% YoY); raises FY2026 guidance","event_type":"earnings","confidence":"high","bullets":["Q1 GAAP net income $89M ($0.69 EPS); non-GAAP net income $123M ($0.96 EPS).","SUBLOCADE net revenue $232M (+32% YoY) driven by 20% dispense unit growth.","Record Q1 adjusted EBITDA $164M (+112% YoY); cash and investments $201M.","Raised FY2026 guidance: net revenue $1.215-1.285B; adj. EBITDA $620-660M.","Discontinued INDV-6001 development; INDV-2000 failed Ph2 OUD endpoint."],"consensus_eps_estimate":null,"consensus_eps_actual":0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":317000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106355,"accession_number":"0001625297-26-000015","cik":1625297,"company_name":"Indivior Pharmaceuticals, Inc.","ticker":"INDV","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["1.01","1.02","2.03","3.02","9.01"],"status":"ready","headline":"Indivior issues $500M 0.625% convertible notes due 2031; repays existing debt","event_type":"debt","confidence":"high","bullets":["$500M principal of 0.625% Convertible Senior Notes due March 15, 2031 issued; initial purchasers' option fully exercised for additional $50M.","Initial conversion price of ~$41.66 per share (35% premium over March 12 close); max ~16.2M shares issuable upon conversion.","Proceeds used to prepay all outstanding principal, interest, and fees under November 2024 Note Purchase Agreement; that agreement terminated.","Notes redeemable at Indivior's option after March 20, 2029 if stock exceeds 130% of conversion price for 20 of 30 trading days.","Notes are senior unsecured, structurally subordinated to subsidiary liabilities; interest payable semi-annually on March 15 and September 15."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106354,"accession_number":"0001625297-26-000012","cik":1625297,"company_name":"Indivior Pharmaceuticals, Inc.","ticker":"INDV","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Indivior prices upsized $450M convertible notes at 0.625% due 2031","event_type":"debt","confidence":"high","bullets":["Principal amount $450M (upsized from $400M); 0.625% interest, matures March 15, 2031.","Net proceeds ~$437.7M (~$486.4M if initial purchasers' option fully exercised).","~$239M of proceeds plus $102M cash used to repay term loan and revolver.","Concurrent $75M repurchase of ~2.4M shares from note purchasers at market price.","Initial conversion price ~$41.66/share, a 35% premium over March 12 closing price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106353,"accession_number":"0001625297-26-000008","cik":1625297,"company_name":"Indivior Pharmaceuticals, Inc.","ticker":"INDV","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Indivior announces $400M convertible senior notes offering due 2031; to repay term loan and repurchase up to $75M stock","event_type":"debt","confidence":"high","bullets":["$400M aggregate principal amount of convertible senior notes due 2031, with initial purchasers' option for additional $60M.","Notes are senior unsecured, pay semi-annual interest, redeemable after March 20, 2029 if stock exceeds 130% of conversion price.","Net proceeds used to repay $239M term loan plus $102M cash, repurchase up to $75M of stock from note purchasers, and general corporate purposes.","Conversions settled in cash and possibly shares; noteholders can require repurchase on fundamental change.","Offering is private under Rule 144A; notes and conversion shares not registered under Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106352,"accession_number":"0001193125-26-073363","cik":1625297,"company_name":"Indivior Pharmaceuticals, Inc.","ticker":"INDV","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Indivior Q4 earnings beat; SUBLOCADE rev $252M (+30%); new $400M buyback; FY26 guidance reaffirmed","event_type":"earnings","confidence":"high","bullets":["Q4 total net revenue $358M (+20% YoY); SUBLOCADE net revenue $252M (+30%); GAAP diluted EPS $0.79 vs $0.17","Non-GAAP Q4 net income $107M ($0.82 diluted EPS); Adjusted EBITDA $142M (+91% YoY)","FY 2025: revenue $1,239M (+4%), SUBLOCADE $856M (+13%); GAAP net income $210M ($1.64 EPS); adj. EBITDA $428M (+20%)","Board authorized new $400M share repurchase program (up to 18 months) for opportunistic deployment","FY 2026 guidance: SUBLOCADE $905M-$945M, adj. EBITDA $535M-$575M, non-GAAP opex $430M-$450M"],"consensus_eps_estimate":null,"consensus_eps_actual":1.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":1239000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106351,"accession_number":"0001193125-26-021660","cik":1625297,"company_name":"Indivior Pharmaceuticals, Inc.","ticker":"INDV","form_type":"8-K","filed_at":"2026-01-26T23:59:59+00:00","items":["1.01","2.03","3.02","3.03","5.03","5.01","5.02","8.01","5.05","7.01","9.01"],"status":"ready","headline":"Indivior completes U.S. Domestication; begins trading on Nasdaq as Delaware corp under INDV","event_type":"other_material","confidence":"high","bullets":["Scheme of Arrangement effective Jan 23, 2026; Indivior U.S. becomes ultimate parent of Indivior U.K.","Common stock starts trading on Nasdaq Jan 26, 2026 under ticker INDV; CUSIP 45579U109.","New 2026 Omnibus Equity Plan authorizes 17.5M shares; non-employee director annual cash retainer $75k-$100k.","Directors and executive officers of Indivior U.K. continue in same roles at Indivior U.S.","Note Purchase Agreement amended to reflect Indivior U.S. as reporting entity; indemnification agreements adopted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106350,"accession_number":"0001193125-26-006993","cik":1625297,"company_name":"Indivior Pharmaceuticals, Inc.","ticker":"INDV","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Indivior provides FY2026 guidance: revenue $1.125B-$1.195B, Adj. EBITDA $535M-$575M","event_type":"other_material","confidence":"high","bullets":["Total net revenue expected $1,125M-$1,195M; SUBLOCADE net revenue $905M-$945M.","Non-GAAP operating expenses guided at $430M-$450M; adjusted EBITDA $535M-$575M.","Completed Phase I of Indivior Action Agenda with annual operating expense savings of at least $150M.","Shareholders approved U.K. to U.S. domicile change; expected effective Jan 26, 2026.","Concluded DOJ matter by paying $295M in full; entered Phase II focused on accelerating growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122687,"accession_number":"0001625297-25-000078","cik":1625297,"company_name":"Indivior Pharmaceuticals, Inc.","ticker":"INDV","form_type":"8-K","filed_at":"2025-12-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Indivior added to S&P SmallCap 600 index effective December 22, 2025","event_type":"other_material","confidence":"high","bullets":["Inclusion in S&P SmallCap 600 index effective today, December 22, 2025.","CEO Joe Ciaffoni cites alignment with sharpened U.S. business profile and commitment to SUBLOCADE.","S&P SmallCap 600 comprises 600 U.S. small-cap companies with market caps between $1.2B and $8.0B.","Addition expected to increase visibility and potential passive fund inflows for INDV shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122686,"accession_number":"0001625297-25-000076","cik":1625297,"company_name":"Indivior Pharmaceuticals, Inc.","ticker":"INDV","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Indivior CEO and CFO receive base salary increases effective Jan 1, 2026","event_type":"leadership","confidence":"high","bullets":["CEO Joseph Ciaffoni salary increased from $1,050,000 to $1,115,000.","CFO Ryan Preblick salary increased from $559,000 to $604,000.","Changes effective January 1, 2026, approved by Board on Dec 12, 2025.","Based on competitive market review and Compensation Committee recommendation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122685,"accession_number":"0001625297-25-000072","cik":1625297,"company_name":"Indivior Pharmaceuticals, Inc.","ticker":"INDV","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Indivior shareholders approve scheme of arrangement to restructure, court hearing Jan 22, 2026","event_type":"other_material","confidence":"high","bullets":["Amended articles effective Dec 11 to facilitate scheme ensuring all shareholders become holders of Indivior Pharmaceuticals shares.","Court meeting: 94,968,161 votes for (99.9%) vs 46,544 against; passed by required majorities.","Extraordinary General Meeting: all 6 special resolutions passed with over 79 million votes for each.","Completion subject to High Court sanction hearing expected January 22, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122684,"accession_number":"0001625297-25-000069","cik":1625297,"company_name":"Indivior Pharmaceuticals, Inc.","ticker":"INDV","form_type":"8-K","filed_at":"2025-11-20T23:59:59+00:00","items":["1.02","7.01","9.01"],"status":"ready","headline":"Indivior pays $295M to DOJ, concludes legacy resolution agreement","event_type":"regulatory","confidence":"high","bullets":["Paid $295M in full to DOJ using cash on hand, resolving 2020 Resolution Agreement.","Resolution Agreement terminated on November 20, 2025.","CEO Joe Ciaffoni says milestone removes significant liability and simplifies capital structure.","Company reaffirms commitment to compliance and transparency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122683,"accession_number":"0001628280-25-052210","cik":1625297,"company_name":"Indivior Pharmaceuticals, Inc.","ticker":"INDV","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Indivior proposes re-domestication from UK to Delaware; shareholder vote set for Dec 11, 2025","event_type":"other_material","confidence":"high","bullets":["Scheme circular filed: EGM on Dec 11, 2025 to vote on re-domestication via scheme of arrangement.","New holding company would be Indivior Pharmaceuticals, Inc. (Delaware); shares to trade on Nasdaq.","Court approval and shareholder vote required; SEC registration exemption under Section 3(a)(10).","Indivior shares expected to cease trading on Nasdaq before effective date; new shares commence same day.","Board unanimously recommends voting in favor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122682,"accession_number":"0001193125-25-257381","cik":1625297,"company_name":"Indivior Pharmaceuticals, Inc.","ticker":"INDV","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Indivior Q3 net revenue $314M (+2% YoY); raises FY2025 guidance materially","event_type":"earnings","confidence":"high","bullets":["SUBLOCADE net revenue $219M (+15% YoY); U.S. SUBLOCADE up 14% to $203M.","Adjusted EBITDA $120M (+14% YoY); non-GAAP diluted EPS $0.72 vs $0.49 YoY.","FY2025 net revenue guidance raised to $1.18-1.22B; adjusted EBITDA now $400-420M.","Plans to exit several ROW markets, discontinue OPVEE sales support, saving at least $150M annually from 2026.","Cash and investments $473M at Q3 end, up $125M from year-end 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":881000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122680,"accession_number":"0001625297-25-000064","cik":1625297,"company_name":"Indivior Pharmaceuticals, Inc.","ticker":"INDV","form_type":"8-K/A","filed_at":"2025-10-30T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Indivior estimates $105-130M restructuring charges; exits six non-US markets","event_type":"other_material","confidence":"high","bullets":["Total pre-tax restructuring charges estimated at $105-130M, with $65M recognized in Q3 2025.","Plans to exit markets: UK, Ireland, Sweden, Israel, Finland, Italy under Action Agenda Phase I.","Expects at least $150M annual operating expense savings starting in 2026.","Cash portion of charges $73-92M; includes severance, real estate, asset impairments, contract terminations.","Headcount reductions cost $33-37M; real estate consolidation $15-21M; asset impairments $21-27M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122681,"accession_number":"0001628280-25-043293","cik":1625297,"company_name":"Indivior Pharmaceuticals, Inc.","ticker":"INDV","form_type":"8-K","filed_at":"2025-10-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Indivior proposes redomiciliation to Delaware via new US parent IPI","event_type":"other_material","confidence":"high","bullets":["Each Indivior PLC share exchanged for one share of new Delaware corporation Indivior Pharmaceuticals, Inc. (IPI).","Timeline: shareholder circular mid-Nov 2025, EGM early Dec 2025, effective late Jan 2026.","Scheme requires approval by 75% in value and majority in number of shareholders voting at EGM.","No additional equity raised; IPI stock will trade on Nasdaq under symbol INDV.","Proposed change aims to expand US capital markets presence and simplify governance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139372,"accession_number":"0001625297-25-000059","cik":1625297,"company_name":"Indivior Pharmaceuticals, Inc.","ticker":"INDV","form_type":"8-K","filed_at":"2025-08-26T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Indivior announces restructuring charges of $39-$50 million as part of Indivior Action Agenda","event_type":"other_material","confidence":"high","bullets":["Headcount reductions expected to incur pre-tax severance charges of approximately $16 to $19 million in Q3 2025.","Real estate consolidation and exit costs estimated at $15 to $22 million pre-tax, including leasehold improvements and asset write-downs.","Consulting, legal, and tax planning expenses of about $8 to $9 million pre-tax, recognized in Q3 2025.","Company is exploring strategic alternatives for OPVEE and its non-U.S. business, which could result in further one-time costs.","Restructuring charges will be excluded from non-GAAP financial measures, consistent with reporting practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139371,"accession_number":"0001625297-25-000056","cik":1625297,"company_name":"Indivior Pharmaceuticals, Inc.","ticker":"INDV","form_type":"8-K","filed_at":"2025-08-22T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Indivior PLC enters new employment agreements with CFO Ryan Preblick; no changes to compensation or role","event_type":"leadership","confidence":"high","bullets":["New employment agreement for CFO Ryan Preblick, effective Jan 1, 2025, aligns with current U.S. executive forms.","No changes to compensation, responsibilities, or title from prior 2020 agreement.","Annual base salary remains $558,819; cash bonus target at 60% of base salary (max 120%).","LTIP annual award anticipated at 400% of base salary, subject to Compensation Committee discretion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139369,"accession_number":"0001628280-25-037425","cik":1625297,"company_name":"Indivior Pharmaceuticals, Inc.","ticker":"INDV","form_type":"8-K/A","filed_at":"2025-08-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Indivior assigns new director Kingsley to Audit & Risk and Compensation committees","event_type":"leadership","confidence":"high","bullets":["Stuart A. (Tony) Kingsley appointed non-executive director effective July 1, 2025.","He will serve on the Audit & Risk Committee and the Compensation Committee.","Appointment previously disclosed; amendment adds committee assignment details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139370,"accession_number":"0001193125-25-169947","cik":1625297,"company_name":"Indivior Pharmaceuticals, Inc.","ticker":"INDV","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Indivior raises FY 2025 guidance after Q2 beat; SUBLOCADE revenue up 9%","event_type":"earnings","confidence":"high","bullets":["Q2 total net revenue $302M (+1% YoY); net income $18M ($0.14 EPS); non-GAAP diluted EPS $0.51.","SUBLOCADE net revenue $209M (+9% YoY, +19% vs Q1'25); U.S. SUBLOCADE $195M (+9% YoY).","FY 2025 guidance raised: net revenue $1.03B-$1.08B (prior $955M-$1.025B); adjusted EBITDA $275M-$300M (prior $220M-$260M).","Adjusted EBITDA Q2 $88M vs $93M Q2'24; cash and investments $538M at Q2 end."],"consensus_eps_estimate":null,"consensus_eps_actual":0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":568000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156957,"accession_number":"0001625297-25-000046","cik":1625297,"company_name":"Indivior Pharmaceuticals, Inc.","ticker":"INDV","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Indivior added to Russell 2000 and 3000 indexes effective June 30, 2025","event_type":"other","confidence":"high","bullets":["Inclusion follows 2025 Russell indexes annual reconstitution; membership lasts one year.","CEO notes 85% of 2024 net revenue was U.S.-generated, mainly from SUBLOCADE.","About $10.6 trillion in assets benchmarked to U.S. Russell indexes (FTSE Russell data).","Stock also automatically added to corresponding growth and value indexes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156956,"accession_number":"0001625297-25-000042","cik":1625297,"company_name":"Indivior Pharmaceuticals, Inc.","ticker":"INDV","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Indivior appoints Tony Kingsley to board; directors adopt equity purchase plan","event_type":"leadership","confidence":"high","bullets":["Appointed Tony Kingsley as independent non-executive director effective July 1, 2025.","Kingsley appointed per Oaktree relationship agreement; former CEO of Scholar Rock and Stablix.","Five US non-executive directors entered JP Morgan purchase plan; company funds ~70% of after-tax retainer into shares.","UK director Juliet Thompson bought 1,925 shares on June 11; company to reimburse over next year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156955,"accession_number":"0001625297-25-000035","cik":1625297,"company_name":"Indivior Pharmaceuticals, Inc.","ticker":"INDV","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Indivior to cancel London Stock Exchange secondary listing, maintain Nasdaq primary listing","event_type":"other_material","confidence":"high","bullets":["London delisting effective July 25, 2025; last trading on LSE July 24, 2025.","Over 80% of net revenue from US; 75% of trading volume on Nasdaq; over 70% of shareholders by value US-based.","Nasdaq listing under INDV unaffected; direct holders and DTC broker/custodian holders unaffected.","Holders of UK Depositary Interests and Corporate Sponsored Nominee facility advised to convert holdings for Nasdaq trading.","UK Takeover Code remains applicable for 2 years after delisting; mandatory offer rules unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156954,"accession_number":"0001193125-25-132699","cik":1625297,"company_name":"Indivior Pharmaceuticals, Inc.","ticker":"INDV","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Indivior posts updated corporate presentation June 2025; content not fully disclosed","event_type":"other_material","confidence":"low","bullets":["Company added 'Corporate Presentation June 2025' to its investor relations website on June 2, 2025.","Presentation furnished as Exhibit 99.1; full text not provided in SEC filing excerpt.","No specific financial guidance, clinical data, or operational updates available from truncated exhibit.","Investors should refer to the full presentation on Indivior's IR page for details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156951,"accession_number":"0001193125-25-116997","cik":1625297,"company_name":"Indivior Pharmaceuticals, Inc.","ticker":"INDV","form_type":"8-K/A","filed_at":"2025-05-12T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Indivior corrects AGM vote tally for Dr. Wheadon election: against votes now 14.6M","event_type":"other_material","confidence":"high","bullets":["Corrected votes against Dr. David Wheadon's election from 4,624,894 to 14,624,894.","All other AGM voting results remain unchanged per the amendment filed May 9, 2025.","Dr. Wheadon was elected with 65.3M votes for (81.71%) and 14.6M against (18.29%).","The correction was disclosed via RNS and furnished as Exhibit 99.1 to this 8-K/A."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156953,"accession_number":"0001625297-25-000032","cik":1625297,"company_name":"Indivior Pharmaceuticals, Inc.","ticker":"INDV","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["5.02","1.01","5.03","5.07","7.01","9.01"],"status":"ready","headline":"Indivior CEO transition finalized as Ciaffoni takes over; articles amended for Nasdaq primary listing","event_type":"leadership","confidence":"high","bullets":["Joe Ciaffoni commenced as CEO on May 8, 2025, following shareholder approval of remuneration policy.","Mark Crossley stepped down as CEO and director; separation terms previously filed.","Shareholders approved new articles of association with changes, including annual director re-elections and shift to Nasdaq as primary exchange.","All 19 resolutions at the 2025 AGM passed by poll; voter turnout ~64%.","New articles remove LSE references and adjust meetings/proxy rules; full text filed as Exhibit 3.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156952,"accession_number":"0001193125-25-091736","cik":1625297,"company_name":"Indivior Pharmaceuticals, Inc.","ticker":"INDV","form_type":"8-K","filed_at":"2025-04-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Indivior Q1 net revenue $266M, in line; GAAP EPS $0.38, non-GAAP $0.41; FY guidance unchanged","event_type":"earnings","confidence":"high","bullets":["Net revenue $266M (-6% YoY), in line with expectations; U.S. net revenue $222M (-8%).","SUBLOCADE NR $176M (-2% YoY); FY 2025 guidance unchanged at $725M-$765M.","GAAP diluted EPS $0.38 (down 15%); non-GAAP diluted EPS $0.41 (down 2%).","SG&A $132M (-8% YoY non-GAAP) reflects cost savings; FY non-GAAP SG&A guided $525M-$535M.","Revised prior financials to correct Branded Fee accrual (immaterial $6M overstatement in 2024)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":266000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175331,"accession_number":"0001625297-25-000025","cik":1625297,"company_name":"Indivior Pharmaceuticals, Inc.","ticker":"INDV","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Indivisor names Joe Ciaffoni CEO; proposes incentive plan with share price targets up to $35","event_type":"leadership","confidence":"high","bullets":["Joe Ciaffoni to become CEO effective upon shareholder approval of new Directors' Remuneration Policy at May 8, 2025 AGM.","On-hire PSU award up to 1.575M shares vests based on VWAP targets: $15, $20, $25, $30, $35 over 1–5 years.","On-hire RSU award of 525,000 shares with cliff vest on 3rd anniversary of start date.","Proposed policy increases LTIP on-target grant to 400% of salary in 2026 and 700% in 2027.","Benchmarked vs US biopharma peers; CEO's potential dilution <2% of value created for shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175330,"accession_number":"0001625297-25-000021","cik":1625297,"company_name":"Indivior Pharmaceuticals, Inc.","ticker":"INDV","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["1.01","5.02"],"status":"ready","headline":"Indivior appoints Joe Ciaffoni as CEO, reduces board to 7, enters amended Oaktree deal","event_type":"leadership","confidence":"high","bullets":["Joe Ciaffoni appointed CEO effective after 2025 AGM but no later than Aug 1, 2025; Mark Crossley remains CEO until then.","Ciaffoni gets base salary $1,050,000, bonus target 100% of salary, max 200%; on-hire PSUs worth 12x salary (up to 1.575M shares) and RSUs 4x salary (up to 525K shares).","Board reduced to 7 directors at 2025 AGM; Peter Bains and Jo LeCouilliard not standing for re-election; Robert Schriesheim resigned effective March 2.","Amended relationship with Oaktree: board to be 8 after search for one new independent director by July 1; Daniel Ninivaggi chairs Nomination Committee.","Barbara Ryan to succeed Jo LeCouilliard as Chair of Compensation Committee after the 2025 AGM."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}